AU2001274860A1 - Process for reducing antibody response against xenografts - Google Patents

Process for reducing antibody response against xenografts

Info

Publication number
AU2001274860A1
AU2001274860A1 AU2001274860A AU7486001A AU2001274860A1 AU 2001274860 A1 AU2001274860 A1 AU 2001274860A1 AU 2001274860 A AU2001274860 A AU 2001274860A AU 7486001 A AU7486001 A AU 7486001A AU 2001274860 A1 AU2001274860 A1 AU 2001274860A1
Authority
AU
Australia
Prior art keywords
response against
antibody response
reducing antibody
against xenografts
xenografts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001274860A
Inventor
Michel Awwad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotransplant Inc
Original Assignee
Biotransplant Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotransplant Inc filed Critical Biotransplant Inc
Publication of AU2001274860A1 publication Critical patent/AU2001274860A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
    • C07G3/00—Glycosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001274860A 2000-05-18 2001-05-18 Process for reducing antibody response against xenografts Abandoned AU2001274860A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20504600P 2000-05-18 2000-05-18
US60205046 2000-05-18
PCT/US2001/016195 WO2001087310A1 (en) 2000-05-18 2001-05-18 Process for reducing antibody response against xenografts

Publications (1)

Publication Number Publication Date
AU2001274860A1 true AU2001274860A1 (en) 2001-11-26

Family

ID=22760560

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001274860A Abandoned AU2001274860A1 (en) 2000-05-18 2001-05-18 Process for reducing antibody response against xenografts

Country Status (3)

Country Link
US (1) US20020168371A1 (en)
AU (1) AU2001274860A1 (en)
WO (1) WO2001087310A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005521497A (en) * 2002-03-25 2005-07-21 ワシントン・ユニバーシティ Chimeric pancreas
AU2003245752A1 (en) * 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
EP1613344A2 (en) * 2003-03-31 2006-01-11 Greenville Hospital System Anti-tumor vasculature effects of human serum albumin derivatives
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
CN106841634B (en) * 2017-01-04 2019-01-22 深圳市第二人民医院 Non- Gal xenoantibody detection method in a kind of human serum

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0991321A4 (en) * 1997-02-05 2002-01-30 Gen Hospital Corp Tolerance to natural antibody antigens
AU5623398A (en) * 1997-03-07 1998-09-22 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds

Also Published As

Publication number Publication date
US20020168371A1 (en) 2002-11-14
WO2001087310A1 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
AU2001247893A1 (en) Method for facilitating commercial transactions
AU2002210409A1 (en) Ethanol process
AU2002214225A1 (en) Process control for micro-lithography
AU2001275097A1 (en) Gap welding process
AU2001273556A1 (en) Manufacturing process for alpha-olefins
AU2001282890A1 (en) Immunosensor
AU2001237471A1 (en) Immunochemical methods
AU2001239243A1 (en) Method for producing nanosuspensions
AU2002213972A1 (en) Method for producing polyisobutenylphenoles
AU2001227953A1 (en) Methods for raising rabbits
AU2002210535A1 (en) Method for producing melamine
AU2001291313A1 (en) Process for making 3-amino-2-chloro-4-methylpyridine
AU2001220281A1 (en) Rollerboard for road-skiing
AU2001290623A1 (en) Interbank process
AU2001274860A1 (en) Process for reducing antibody response against xenografts
AU2001237530A1 (en) Method
AU2002218440A1 (en) New process
AU2002221132A1 (en) Novel antibody
AU2001266031A1 (en) Process for drying amoxicillin
AU2001241636A1 (en) Halotherapy method
AU2001294285A1 (en) Apparatus for manufacturing structural panels
AU2001267769A1 (en) Process
AU5822601A (en) Headstock
AU2002220757A1 (en) Method for obtaining azaerythromycin
AU2002212224A1 (en) Method for producing delta1-pyrrolines